Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 146

1.

Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women.

Chlebowski RT, Anderson GL, Gass M, Lane DS, Aragaki AK, Kuller LH, Manson JE, Stefanick ML, Ockene J, Sarto GE, Johnson KC, Wactawski-Wende J, Ravdin PM, Schenken R, Hendrix SL, Rajkovic A, Rohan TE, Yasmeen S, Prentice RL; WHI Investigators..

JAMA. 2010 Oct 20;304(15):1684-92. doi: 10.1001/jama.2010.1500.

2.

Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial.

Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D, Rodabough RJ, Gilligan MA, Cyr MG, Thomson CA, Khandekar J, Petrovitch H, McTiernan A; WHI Investigators..

JAMA. 2003 Jun 25;289(24):3243-53.

PMID:
12824205
3.

Continuous Combined Estrogen Plus Progestin and Endometrial Cancer: The Women's Health Initiative Randomized Trial.

Chlebowski RT, Anderson GL, Sarto GE, Haque R, Runowicz CD, Aragaki AK, Thomson CA, Howard BV, Wactawski-Wende J, Chen C, Rohan TE, Simon MS, Reed SD, Manson JE.

J Natl Cancer Inst. 2015 Dec 14;108(3). pii: djv350. doi: 10.1093/jnci/djv350.

4.

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.

Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J; Writing Group for the Women's Health Initiative Investigators..

JAMA. 2002 Jul 17;288(3):321-33.

PMID:
12117397
5.

Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials.

Manson JE, Chlebowski RT, Stefanick ML, Aragaki AK, Rossouw JE, Prentice RL, Anderson G, Howard BV, Thomson CA, LaCroix AZ, Wactawski-Wende J, Jackson RD, Limacher M, Margolis KL, Wassertheil-Smoller S, Beresford SA, Cauley JA, Eaton CB, Gass M, Hsia J, Johnson KC, Kooperberg C, Kuller LH, Lewis CE, Liu S, Martin LW, Ockene JK, O'Sullivan MJ, Powell LH, Simon MS, Van Horn L, Vitolins MZ, Wallace RB.

JAMA. 2013 Oct 2;310(13):1353-68. doi: 10.1001/jama.2013.278040.

6.

Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial.

Shumaker SA, Legault C, Rapp SR, Thal L, Wallace RB, Ockene JK, Hendrix SL, Jones BN 3rd, Assaf AR, Jackson RD, Kotchen JM, Wassertheil-Smoller S, Wactawski-Wende J; WHIMS Investigators..

JAMA. 2003 May 28;289(20):2651-62.

PMID:
12771112
7.

Breast Cancer After Use of Estrogen Plus Progestin and Estrogen Alone: Analyses of Data From 2 Women's Health Initiative Randomized Clinical Trials.

Chlebowski RT, Rohan TE, Manson JE, Aragaki AK, Kaunitz A, Stefanick ML, Simon MS, Johnson KC, Wactawski-Wende J, O'Sullivan MJ, Adams-Campbell LL, Nassir R, Lessin LS, Prentice RL.

JAMA Oncol. 2015 Jun;1(3):296-305. doi: 10.1001/jamaoncol.2015.0494.

PMID:
26181174
8.

Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial.

LaCroix AZ, Chlebowski RT, Manson JE, Aragaki AK, Johnson KC, Martin L, Margolis KL, Stefanick ML, Brzyski R, Curb JD, Howard BV, Lewis CE, Wactawski-Wende J; WHI Investigators..

JAMA. 2011 Apr 6;305(13):1305-14. doi: 10.1001/jama.2011.382.

9.

Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study.

Shumaker SA, Legault C, Kuller L, Rapp SR, Thal L, Lane DS, Fillit H, Stefanick ML, Hendrix SL, Lewis CE, Masaki K, Coker LH; Women's Health Initiative Memory Study..

JAMA. 2004 Jun 23;291(24):2947-58.

PMID:
15213206
10.

Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial.

Anderson GL, Judd HL, Kaunitz AM, Barad DH, Beresford SA, Pettinger M, Liu J, McNeeley SG, Lopez AM; Women's Health Initiative Investigators..

JAMA. 2003 Oct 1;290(13):1739-48.

PMID:
14519708
11.

Estrogen plus progestin and risk of venous thrombosis.

Cushman M, Kuller LH, Prentice R, Rodabough RJ, Psaty BM, Stafford RS, Sidney S, Rosendaal FR; Women's Health Initiative Investigators..

JAMA. 2004 Oct 6;292(13):1573-80.

PMID:
15467059
12.

New-onset breast tenderness after initiation of estrogen plus progestin therapy and breast cancer risk.

Crandall CJ, Aragaki AK, Chlebowski RT, McTiernan A, Anderson G, Hendrix SL, Cochrane BB, Kuller LH, Cauley JA.

Arch Intern Med. 2009 Oct 12;169(18):1684-91. doi: 10.1001/archinternmed.2009.303.

13.

Estrogen-plus-progestin use and mammographic density in postmenopausal women: Women's Health Initiative randomized trial.

McTiernan A, Martin CF, Peck JD, Aragaki AK, Chlebowski RT, Pisano ED, Wang CY, Brunner RL, Johnson KC, Manson JE, Lewis CE, Kotchen JM, Hulka BS; Women's Health Initiative Mammogram Density Study Investigators..

J Natl Cancer Inst. 2005 Sep 21;97(18):1366-76.

PMID:
16174858
14.
15.

Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial.

Rapp SR, Espeland MA, Shumaker SA, Henderson VW, Brunner RL, Manson JE, Gass ML, Stefanick ML, Lane DS, Hays J, Johnson KC, Coker LH, Dailey M, Bowen D; WHIMS Investigators..

JAMA. 2003 May 28;289(20):2663-72.

PMID:
12771113
16.

Postmenopausal hormone use and the risk of nephrolithiasis: results from the Women's Health Initiative hormone therapy trials.

Maalouf NM, Sato AH, Welch BJ, Howard BV, Cochrane BB, Sakhaee K, Robbins JA.

Arch Intern Med. 2010 Oct 11;170(18):1678-85. doi: 10.1001/archinternmed.2010.342.

17.

Estrogen plus progestin and colorectal cancer in postmenopausal women.

Chlebowski RT, Wactawski-Wende J, Ritenbaugh C, Hubbell FA, Ascensao J, Rodabough RJ, Rosenberg CA, Taylor VM, Harris R, Chen C, Adams-Campbell LL, White E; Women's Health Initiative Investigators..

N Engl J Med. 2004 Mar 4;350(10):991-1004.

18.

Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial.

Wassertheil-Smoller S, Hendrix SL, Limacher M, Heiss G, Kooperberg C, Baird A, Kotchen T, Curb JD, Black H, Rossouw JE, Aragaki A, Safford M, Stein E, Laowattana S, Mysiw WJ; WHI Investigators..

JAMA. 2003 May 28;289(20):2673-84.

PMID:
12771114
19.

Estrogen plus progestin and breast cancer incidence and mortality in the Women's Health Initiative Observational Study.

Chlebowski RT, Manson JE, Anderson GL, Cauley JA, Aragaki AK, Stefanick ML, Lane DS, Johnson KC, Wactawski-Wende J, Chen C, Qi L, Yasmeen S, Newcomb PA, Prentice RL.

J Natl Cancer Inst. 2013 Apr 17;105(8):526-35. doi: 10.1093/jnci/djt043.

20.

Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin.

Heiss G, Wallace R, Anderson GL, Aragaki A, Beresford SA, Brzyski R, Chlebowski RT, Gass M, LaCroix A, Manson JE, Prentice RL, Rossouw J, Stefanick ML; WHI Investigators..

JAMA. 2008 Mar 5;299(9):1036-45. doi: 10.1001/jama.299.9.1036.

PMID:
18319414

Supplemental Content

Support Center